Kenvue Inc. (NYSE:KVUE) Receives Consensus Rating of “Hold” from Brokerages

Kenvue Inc. (NYSE:KVUE) has earned a consensus recommendation of “Hold” from the sixteen ratings firms that are presently covering the company, MarketBeat Ratings reports. Thirteen investment analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $19.5833.

KVUE has been the subject of a number of research reports. Canaccord Genuity Group lifted their target price on shares of Kenvue from $17.00 to $18.00 and gave the company a “hold” rating in a research note on Wednesday, February 18th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Kenvue in a research note on Friday, January 9th. Argus upgraded Kenvue to a “hold” rating in a report on Friday, March 6th. Barclays lifted their price objective on Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a research report on Friday, March 6th. Finally, UBS Group boosted their target price on Kenvue from $17.00 to $19.00 and gave the company a “neutral” rating in a research note on Wednesday, February 18th.

Hedge Funds Weigh In On Kenvue

A number of hedge funds have recently added to or reduced their stakes in KVUE. Elyxium Wealth LLC acquired a new stake in Kenvue in the fourth quarter valued at approximately $26,000. Physician Wealth Advisors Inc. grew its position in Kenvue by 67.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after acquiring an additional 618 shares in the last quarter. Cornerstone Planning Group LLC increased its stake in shares of Kenvue by 705.2% during the 3rd quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company’s stock worth $25,000 after purchasing an additional 1,361 shares during the last quarter. NBT Bank N A NY increased its stake in shares of Kenvue by 180.3% during the 3rd quarter. NBT Bank N A NY now owns 1,564 shares of the company’s stock worth $25,000 after purchasing an additional 1,006 shares during the last quarter. Finally, Salomon & Ludwin LLC bought a new position in shares of Kenvue during the 3rd quarter valued at $25,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Price Performance

NYSE KVUE opened at $17.53 on Friday. The company has a 50 day simple moving average of $17.99 and a 200-day simple moving average of $17.14. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.96 and a quick ratio of 0.68. The firm has a market capitalization of $33.59 billion, a price-to-earnings ratio of 22.76, a price-to-earnings-growth ratio of 4.00 and a beta of 0.51. Kenvue has a 52-week low of $14.02 and a 52-week high of $25.17.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Tuesday, February 17th. The company reported $0.27 EPS for the quarter, beating analysts’ consensus estimates of $0.22 by $0.05. The firm had revenue of $3.78 billion for the quarter, compared to the consensus estimate of $3.68 billion. Kenvue had a net margin of 9.72% and a return on equity of 19.72%. The firm’s revenue was up 3.2% on a year-over-year basis. During the same period in the previous year, the firm posted $0.26 earnings per share. Equities research analysts predict that Kenvue will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, February 25th. Stockholders of record on Wednesday, February 11th were issued a dividend of $0.2075 per share. This represents a $0.83 annualized dividend and a dividend yield of 4.7%. The ex-dividend date was Wednesday, February 11th. Kenvue’s payout ratio is currently 107.79%.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.